NSF
NSF offers extensive industry expertise with a solid roster of exregulators, specializing in delivering consulting, training and auditing services and solutions to the world’s largest and most dynamic companies in the pharmaceutical and biotech industries.
device companies. Its solutions span industry audit preparation and mock inspections, post-inspection response and support, regulatory submission strategy, quality system consulting, remediation projects, trainings and data integrity support.
Navigating Regulatory Requirements For emerging companies in particular, early integration of regulatory compliance can determine speed to market. NSF’s role as a contract research organization often involves helping organizations navigate everchanging regulations to deliver consistent outcomes, as evidenced by its 25 market approvals. Local organizations benefit from access to global expertise as NSF’s Life Science division has experience working with over 1,500 global companies in 68 different countries to maneuver a changing matrix of regulations and deliver life-saving and life-enhancing medical products and pharmaceuticals to patients. NSF helps those in the industry mitigate risk, ensure compliance with international and FDA regulations and standards, and apply effective quality systems. In Michigan’s life science startup ecosystem, including research universities, venture capital and incubators, this regulatory fluency is increasingly viewed as a competitive advantage.
Innovation and Growth NSF represents one component of a larger structure supporting the state’s life science momentum. From medical devices, pharmaceuticals and clinical research to biotech and in vitro
diagnostics consulting, the organization’s testing, certification and standards development work intersects with many of the industries driving Michigan’s next phase of life sciences growth. This work can be seen with Amarex, an NSF company, and its achievement of the Orphan Drug Designation for Gibson Oncology’s Novel LMP744 cancer treatment. The designation was pivotal in marking a milestone in glioblastoma treatment with glioma treatment that crosses the blood-brain barrier at 10 times the concentration needed to kill cancer cells. Amarex also managed the US FDA-authorized clinical trial launch to support new treatment development for progeria, or Hutchinson-Gilford syndrome. As regulatory complexity increases, particularly in areas such as chemical exposure limits, environmental contaminants and international harmonization, thirdparty certification bodies like NSF are sure to play an even more significant role in innovation. For life science organizations, the ability to translate research breakthroughs into compliant, marketready products depends not only on scientific ingenuity but also on robust validation frameworks.
With the life sciences industry continually evolving, the work between innovators and organizations like NSF will be as critical as the technologies themselves. nsf.org
BIOMATTERS ® | SPRING 2026
7